More on APRE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.67 |
|
|||
| Open | $0.67 | ||||
| 52 Wk High | $0.08 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $0.67 | ||||
| Day Low | $0.67 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 249 | ||||
- Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: LYTTON LAURENCE W
- Form 10-Q Aprea Therapeutics, Inc. For: Jun 30
- Form 8-K Aprea Therapeutics, Inc. For: Aug 12
- Aprea Therapeutics Announces Second Quarter 2026 Financial Results
- Lipocine names former Johnson & Johnson executive to its board
- Lipocine Appoints Michael J. Grissinger to Board of Directors
- Aprea expands cancer trial sites and plans Q4 2026 data update
- Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
- Form 8-K Aprea Therapeutics, Inc. For: Jul 23
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Entities mentioned with APRE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maxim Group | View Related Stories »
- Show More...
